OBJECTIVES:   To propose and test an indicator (FBI) to determine the frequency of FB in the studies of EEHTs. METHODS: Using an interdisciplinary panel we propose an FB indicator (FBI) on a group of EEHT. The FBI is the probability that the results of a randomly selected paper afford economic benefits to its funder. The FBI can't be used to judge individual papers, but instead allows a comparison of FB among different sets of studies (Journals, by periods, by countries, etc). In calculating FBI the numerator is the sum of the studies that favor the funder and those omitting their source of funding; the denominator is the total papers. The test was conducted on the 2008 European EEHTs indexed in PubMed.  RESULTS: We designed the FBI to estimate FB at EEHTs. We identified 88 potential EEHTs, of which 56 abstracts met the inclusion criteria, 52 of these were full papers thus submitted to analysis. Testing found: 73.07% of the papers stated the source of funding and of these, 76.31% were funded by health technologies companies, 96.55% of these papers reported results benefiting the funding company. The FBI for Europe in 2008 was 80.76%. FB decreased between the first and second half of 2008, from 81.25% to 72.22%.  CONCLUSIONS: We’ve presented an indicator that estimates FB probability in EEHTs. The FBI is applicable to sets of papers, it determines their FB and facilitates research control. Its systematic measurement can generate incentives to decrease FB.  In order to facilitate FBI measurement it is convenient for authors to include within the abstracts: source of funding, whether the funder commercially exploits one of the comparators, whether any of the authors work for a company profiting from one of the comparators, and whether the results of the study favor the funder or the employer.